Pacira BioSciences (PCRX) Income from Continuing Operations (2010 - 2026)

Pacira BioSciences' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 2916000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 39.4% year-over-year to 2916000.0; the TTM figure through Mar 2026 stood at 5138000.0 (up 104.95% YoY), while the FY2025 annual figure was 7034000.0, up 107.07% from the prior year.
• Income from Continuing Operations was 2916000.0 for Q1 2026 at Pacira BioSciences, up from 1637000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 25763000.0 in Q2 2023 to a low of 143466000.0 in Q3 2024.
• Historically, Income from Continuing Operations has averaged 1867411.76 across 5 years, with a median of 5432000.0 in 2025.
• The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations soared 1666.81% in 2023, then slumped 1421.29% in 2024.
• A 5-year view of Income from Continuing Operations shows it stood at 10102000.0 in 2022, then soared by 346.19% to 24870000.0 in 2023, then plunged by 35.5% to 16041000.0 in 2024, then slumped by 89.79% to 1637000.0 in 2025, then soared by 78.13% to 2916000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 2916000.0 (Q1 2026), 1637000.0 (Q4 2025), and 5432000.0 (Q3 2025), per Business Quant data.